Rhythm Biosciences Ltd (ASX: RHY) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Rhythm Biosciences Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $248.33 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 214.08 million
Earnings per share -0.044
Dividend per share N/A
Year To Date Return -23.23%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Rhythm Biosciences Ltd (ASX: RHY)
Latest News

Two happy scientists analysing test results.
Healthcare Shares

Rhythm Biosciences share price lifts 5% on TGA news

The company is hoping to market and sell its cancer test kit in Australia this year.

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Shares in the healthcare company surged after the company released a quarterly update.

Read more »

Group of medical professionals high five
Healthcare Shares

Here’s why the Rhythm (ASX:RHY) share price is up 11% today

The company provided two exciting updates to investors this morning.

Read more »

man jumping along increasing bar graph signifying jump in alumina share price
Healthcare Shares

Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets

The company is looking to launch into new markets.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Rhythm Biosciences (ASX: RHY) share price slumps amid ‘pivotal’ board changes

This healthcare company is developing a blood test to detect colorectal cancer

Read more »

Share Gainers

Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity

This healthcare company is targeting a lucrative market...

Read more »

Group of doctors celebrate by pumping fists in the air
Healthcare Shares

These were the best performing ASX healthcare shares in October

These names sit on the podium for ASX healthcare performers last month.

Read more »

women in a lab carrying out a medical experiment
Healthcare Shares

Here’s why the Rhythm Biosciences share price (ASX:RHY) is jumping higher today

Regulatory momentum filled Rhythm's quarter with positive inflection points.

Read more »

RHY ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Rhythm Biosciences Ltd

Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

RHY Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $1.19 $-0.01 -0.83% 202,091 $1.22 $1.23 $1.19
12 May 2022 $1.20 $-0.01 -0.83% 753,017 $1.29 $1.35 $1.18
11 May 2022 $1.21 $0.02 1.68% 238,984 $1.20 $1.23 $1.17
10 May 2022 $1.19 $0.01 0.85% 585,309 $1.18 $1.25 $1.12
09 May 2022 $1.18 $-0.10 -7.81% 493,668 $1.26 $1.26 $1.18
06 May 2022 $1.28 $0.03 2.40% 312,393 $1.22 $1.30 $1.20
05 May 2022 $1.25 $-0.04 -3.10% 293,060 $1.32 $1.32 $1.25
04 May 2022 $1.29 $0.01 0.78% 426,677 $1.32 $1.39 $1.28
03 May 2022 $1.28 $-0.08 -5.88% 163,766 $1.38 $1.38 $1.28
02 May 2022 $1.36 $-0.03 -2.15% 86,268 $1.37 $1.37 $1.31
29 Apr 2022 $1.40 $0.02 1.45% 148,857 $1.41 $1.42 $1.36
28 Apr 2022 $1.38 $-0.04 -2.82% 129,746 $1.43 $1.46 $1.37
27 Apr 2022 $1.42 $0.12 9.23% 158,166 $1.25 $1.43 $1.25
26 Apr 2022 $1.30 $-0.10 -7.14% 427,140 $1.38 $1.38 $1.25
22 Apr 2022 $1.40 $-0.02 -1.41% 208,113 $1.40 $1.44 $1.33
21 Apr 2022 $1.42 $0.01 0.71% 138,520 $1.42 $1.46 $1.40
20 Apr 2022 $1.41 $-0.05 -3.42% 274,194 $1.48 $1.50 $1.38

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
25 Nov 2021 Otto Buttula Issued 2 $3,710,000
Issue of options.
25 Nov 2021 Trevor Lockett Issued 500 $927,500
Issue of options.
25 Nov 2021 Louis (Lou) Panaccio Issued 150 $278,250
Issue of options.
25 Nov 2021 Eduardo Vom Issued 150 $278,250
Issue of options.
09 Sep 2021 Trevor Lockett Issued 4 $4,000
Rights issue.
09 Sep 2021 Trevor Lockett Issued 4 $3,400
Rights issue.
09 Sep 2021 Eduardo Vom Issued 88 $88,818
Rights issue.
09 Sep 2021 Eduardo Vom Issued 28 $24,139
Rights issue.
09 Sep 2021 Eduardo Vom Issued 60 $51,354
Rights issue.
09 Sep 2021 Louis (Lou) Panaccio Issued 20 $17,000
Rights issue.
09 Sep 2021 Louis (Lou) Panaccio Issued 20 $20,000
Rights issue.
09 Sep 2021 Otto Buttula Issued 685 $582,251
Rights issue.
09 Sep 2021 Otto Buttula Issued 685 $685,002
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Otto Leslie Steven Buttula Executive ChairmanExecutive Director Oct 2019
Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited. Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit and Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Mr Louis (Lou) James Panaccio Non-Executive Director Aug 2017
Mr Panaccio has experience in business and healthcare services. Lou is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Therapeutics, Inc. Lou is also on the board of Unison Housing Limited. He has more than twenty years of experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Dr Trevor John Lockett Executive DirectorTechnical Director Jun 2017
Mr Lockett has over 30 years of research experience, at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT
Mr Glenn Gilbert Chief Executive OfficerManaging Director Dec 2021
Mr Eduardo Vom Non-Executive Director Jun 2020
Mr Vom has over 20 years of experience in technology and development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He currently serves as a non-executive director with privately owned health and wellbeing companies and has experience in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation.
Dr Rachel David Non-Executive Director Dec 2021
Dr David is an experienced senior health and financial services sector executive with understanding of the complex interplay between government, business, media and the community. Her career has spanned over 25 years in healthcare, particularly relating to evidence-based practice and access to new technologies. She is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). This includes the two major listed companies, Medibank and nib. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.
Ms Andrea Steele Company SecretaryGeneral Counsel Feb 2022
Andrea Steele Company SecretaryGeneral Counsel

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Webinvest Pty Ltd 16,666,667 8.24%
Newfound Investments Pty Ltd 10,733,333 5.31%
Ferndale Securities Pty Ltd 10,100,000 4.99%
Loumea Investment Pty Ltd 9,915,000 4.90%
Northern Star Nominees Pty Ltd 7,200,000 3.56%
Mrs Sarah Cameron 6,300,000 3.12%
Rojo Nero Capital Pty Ltd 4,166,668 2.06%
Giokir Pty Ltd 3,400,000 1.68%
Mr Hsien Michael Soo 3,224,783 1.59%
Jawaf Enterprises Pty Ltd 3,150,000 1.56%
Commonwealth Scientific & Industrial Research Organisation 2,500,000 1.24%
Mr Daniel Eddington & Mrs Julie Eddington 2,460,000 1.22%
Ms Natalie Louise Patterson 2,416,666 1.19%
Garnsworthy Pension Fund Pty Ltd 2,250,000 1.11%
Dr Gavin James Shepherd & Mrs Catherine Shepherd 2,000,000 0.99%
E & W Nominee Pty Ltd 2,000,000 0.99%
Dc & Pc Holdings Pty Ltd 1,750,000 0.87%
Mr Richard Stanley De Ravin 1,600,000 0.79%
Dr Paul Maxwell Miller & Mrs Louise Monique Miller 1,509,188 0.75%
HSBC Custody Nominees (Australia) Limited 1,491,945 0.74%